Amova Asset Management Americas Inc. Decreases Stock Holdings in Cerus Corporation $CERS

Amova Asset Management Americas Inc. decreased its holdings in shares of Cerus Corporation (NASDAQ:CERS) by 6.2% in the 3rd quarter, Holdings Channel.com reports. The firm owned 5,685,177 shares of the biotechnology company’s stock after selling 376,952 shares during the quarter. Amova Asset Management Americas Inc.’s holdings in Cerus were worth $9,039,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Cubist Systematic Strategies LLC increased its stake in Cerus by 152.4% in the first quarter. Cubist Systematic Strategies LLC now owns 104,101 shares of the biotechnology company’s stock valued at $145,000 after purchasing an additional 62,854 shares during the period. AQR Capital Management LLC increased its holdings in shares of Cerus by 291.6% in the 1st quarter. AQR Capital Management LLC now owns 1,429,062 shares of the biotechnology company’s stock valued at $1,986,000 after purchasing an additional 1,064,133 shares in the last quarter. Millennium Management LLC lifted its position in shares of Cerus by 12.0% during the 1st quarter. Millennium Management LLC now owns 3,222,327 shares of the biotechnology company’s stock valued at $4,479,000 after acquiring an additional 344,395 shares during the period. Dynamic Technology Lab Private Ltd acquired a new position in Cerus during the first quarter worth $32,000. Finally, Savant Capital LLC lifted its holdings in shares of Cerus by 339.6% in the second quarter. Savant Capital LLC now owns 94,812 shares of the biotechnology company’s stock valued at $134,000 after purchasing an additional 73,244 shares in the last quarter. Institutional investors and hedge funds own 78.37% of the company’s stock.

Cerus Trading Up 5.2%

Cerus stock opened at $2.24 on Thursday. The company has a 50 day moving average price of $2.32 and a 200 day moving average price of $1.84. The firm has a market capitalization of $430.46 million, a price-to-earnings ratio of -28.00 and a beta of 1.51. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.29 and a current ratio of 1.73. Cerus Corporation has a 52 week low of $1.12 and a 52 week high of $2.95.

Cerus (NASDAQ:CERS) last posted its quarterly earnings results on Monday, March 2nd. The biotechnology company reported ($0.01) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.01). Cerus had a negative return on equity of 26.09% and a negative net margin of 7.58%.The company had revenue of $64.58 million during the quarter, compared to the consensus estimate of $59.31 million. Research analysts forecast that Cerus Corporation will post -0.08 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on CERS. Wall Street Zen upgraded shares of Cerus from a “hold” rating to a “buy” rating in a research report on Saturday, November 8th. TD Cowen reissued a “buy” rating on shares of Cerus in a research report on Monday, January 12th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Hold”.

Cerus Company Profile

Cerus Corporation is a biomedical products company dedicated to enhancing the safety of blood transfusions worldwide. Its flagship offering, the INTERCEPT Blood System, employs pathogen reduction technology designed to inactivate a broad spectrum of viruses, bacteria, and parasites in donated platelets and plasma. This approach aims to mitigate the risk of transfusion-transmitted infections and improve blood component safety for patients.

The INTERCEPT platform integrates seamlessly into existing blood center workflows, providing a one-step treatment process for collected blood products.